2025-12-23 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data.

**1) Return Rate Comparison (TMDX vs. S&P 500)**

*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care systems for transplantation therapy.
*   **TMDX Cumulative Return:** 214.22%
*   **S&P 500 (VOO) Cumulative Return:** 76.12%
*   **Divergence:**
    *   Absolute Divergence: 138.1% (TMDX significantly outperformed the S&P 500)
    *   Relative Divergence: 66.1% (The current divergence is in the 66.1th percentile of past divergence data)

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha | Beta | Cap(B) |
|------------|---------|-------|-------|------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.2    |
| 2023-2025  | 135.0%  | 85.5% | 70.0%  | 0.3  | 4.4    |

*   **CAGR:** The Compound Annual Growth Rate has been highly variable, ranging from negative in 2019-2021 to extremely high in subsequent periods. Recent years show strong growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:** Alpha is generally positive, meaning TMDX has been outperforming its benchmark on a risk-adjusted basis. High Alpha values in recent periods indicate strong independent performance.
*   **Beta:** Beta values are low, suggesting that TMDX's price movements are not highly correlated with the overall market (S&P 500).
*   **Cap(B):** Market capitalization has generally been increasing (except for 2022-2024), reaching 4.4B recently, which is a healthy sign of growth and investor confidence.

**Analysis:**

*   TMDX has significantly outperformed the S&P 500, demonstrating strong growth potential.
*   However, the high MDD indicates significant volatility and risk.
*   Positive Alpha values show that TMDX's performance is driven by company-specific factors rather than just market trends.
*   Low Beta suggests that TMDX can provide diversification benefits to a portfolio.
*   Increasing market capitalization is a positive sign for the company's growth.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 127.67
*   **Last Market Data:** Price: 129.35, Previous Close: 127.67, Change: 1.32
*   **5-day SMA:** 123.77
*   **20-day SMA:** 134.25
*   **60-day SMA:** 124.88

**Analysis:**

*   The 5-day SMA is below the 20-day and 60-day SMAs, suggesting a recent downtrend.
*   The recent price increase from 127.67 to 129.35 may indicate a potential rebound.
*   The stock price is showing volatility as it fluctuates around the moving averages.

**3) RSI, PPO, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 25.77 (Oversold)
*   **PPO:** -1.42 (Negative, indicating a downtrend)
*   **Hybrid Signal:** Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** 0.6 (+) (Short-term increase)
*   **Expected Return (%):** 47.6 (Long-term)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates that the stock is oversold, potentially signaling a buying opportunity.
*   The negative PPO confirms the recent downtrend, but the oversold RSI could lead to a reversal.
*   The Hybrid Signal recommends buying the stock, indicating a bullish outlook.
*   The recent increase in relative divergence suggests a short-term upward movement.
*   The high expected return (47.6%) makes TMDX an attractive long-term investment.
*   The price change of 1.32 reflects some recent market fluctuation, but the recent trend suggests a positive market reaction.

**4) Recent News & Significant Events:**

*   **Positive Analyst Outlook:** Multiple articles highlight positive analyst ratings and target price increases (MarketBeat, Zacks).  Canaccord Genuity Group expects the stock price to rise. Zacks highlights reasons to retain the stock.
*   **Institutional Buying:** Bolumsonucanavari.com notes institutional buying supporting the stock.
*   **Q3 Earnings Beat, but Stock Fell:** Yahoo Finance reports that the stock fell despite Q3 earnings beating estimates. This suggests that market expectations were even higher, or there were concerns about future performance.
*   **Insider Sales:** Quiver Quantitative mentions recent insider sales, which can sometimes be a negative signal, but should be considered in the context of overall analyst sentiment and company performance.
*   **Strong Growth Stock:** Nasdaq highlights TMDX as a strong growth stock.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean = 1.67)
*   **Target Price:** Average: 144.73 / High: 170.00 / Low: 114.00
*   **Recent Rating Changes:** Not Provided

**Analysis:**

*   The analyst consensus is overwhelmingly positive, with a "Buy" rating and a significant upside potential based on the average target price.
*   The target price range indicates that analysts expect the stock to appreciate in value.
*   However, the Q3 earnings miss and insider sales should be considered when making investment decisions.

**5) Comprehensive Analysis**

TransMedics Group Inc. (TMDX) presents a compelling but potentially risky investment opportunity.

**Strengths:**

*   **High Growth Potential:** TMDX has significantly outperformed the S&P 500, with a high expected return and strong CAGR in recent periods.
*   **Positive Analyst Sentiment:** Analysts have a consensus "Buy" rating and expect the stock to appreciate in value.
*   **Strong Alpha:** The company's performance is driven by company-specific factors rather than just market trends.
*   **Innovative Technology:** TMDX's focus on organ care systems for transplantation therapy positions it in a growing market.
*   **Recent Hybrid Signal:** Positive Hybrid Signal further pushes the investment attractiveness.

**Weaknesses/Risks:**

*   **High Volatility:** The high MDD indicates significant volatility and risk.
*   **Q3 Earnings Miss:** The stock fell despite Q3 earnings beating estimates, indicating that market expectations are high.
*   **Insider Sales:** Recent insider sales could be a negative signal, but should be viewed together with high analyst expectations.
*   **Low Beta:** Indicates less correlation with S&P 500, and might underperform if S&P 500 trends are generally strong.

**Overall:**

TMDX appears to be a promising growth stock with a strong potential for long-term returns. The recent pullback in price, as indicated by the oversold RSI and negative PPO, could present a buying opportunity.

However, investors should be aware of the high volatility and risks associated with the stock. It is essential to monitor the company's financial performance and analyst ratings closely. The recent insider sales and the Q3 earnings miss should be considered when making investment decisions.

**Recommendation:**

A cautious "Buy" recommendation is warranted for investors with a long-term investment horizon and a high risk tolerance. Investors should consider diversifying their portfolios to mitigate the risks associated with TMDX. A potential strategy is to dollar-cost average into the position, especially during periods of price weakness. Pay close attention to future earnings reports and analyst revisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.